{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:34:56Z","timestamp":1787927696992,"version":"build-2784847793"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004702","name":"Universit\u00e0 degli Studi di Genova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004702","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To date, there is no consensus on how to semi-quantitatively assess brain amyloid PET. Some approaches use late acquisition alone (e.g., ELBA, based on radiomic features), others integrate the early scan (e.g., TDr, which targets the area of maximum perfusion) and structural imaging (e.g., WMR, that compares kinetic behaviour of white and grey matter, or SI based on the kinetic characteristics of the grey matter alone). In this study SUVr, ELBA, TDr, WMR, and SI were compared. The latter \u2014 the most complete one \u2014 provided the reference measure for amyloid burden allowing to assess the efficacy and feasibility in clinical setting of the other approaches.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We used data from 85 patients (aged 44\u201387) who underwent dual time-point PET\/MRI acquisitions. The correlations with SI were computed and the methods compared with the visual assessment. Assuming SUVr, ELBA, TDr, and WMR to be independent measures, we linearly combined them to obtain more robust indices. Finally, we investigated possible associations between each quantifier and age in amyloid-negative patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Each quantifier exhibited excellent agreement with visual assessment and strong correlation with SI (average AUC\u2009=\u20090.99, <jats:italic>\u03c1<\/jats:italic>\u2009=\u20090.91). Exceptions to this were observed for subcortical regions with ELBA and WMR (<jats:italic>\u03c1<\/jats:italic><jats:sub>ELBA<\/jats:sub>\u2009=\u20090.44, <jats:italic>\u03c1<\/jats:italic><jats:sub>WMR<\/jats:sub>\u2009=\u20090.70). The linear combinations showed better performances than the individual methods. Significant associations were observed between TDr, WMR, SI, and age in amyloid-negative patients (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Among the other methods, TDr came closest to the reference with less implementation complexity. Moreover, this study suggests that combining independent approaches gives better results than the individual procedure, so efforts should focus on multi-classifier systems for amyloid PET. Finally, the ability of techniques integrating blood perfusion to depict age-related variations in amyloid load in amyloid-negative subjects demonstrates the goodness of the estimate.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-022-05846-1","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T09:02:54Z","timestamp":1654160574000},"page":"4097-4108","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A comparison of advanced semi-quantitative amyloid PET analysis methods"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5834-8101","authenticated-orcid":false,"given":"Enrico","family":"Peira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Poggiali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Pardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henryk","family":"Barthel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Sabri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Morbelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annachiara","family":"Cagnin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Chincarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Cecchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"issue":"4","key":"5846_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R, Elliott C, Masliah E, Ryan L, Silverberg N. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2018;14(4):535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimer\u2019s Dement"},{"issue":"11","key":"5846_CR2","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.2967\/jnumed.116.185017","volume":"58","author":"H Barthel","year":"2017","unstructured":"Barthel H, Sabri O. Clinical Use and utility of amyloid imaging. J Nucl Medicine. 2017;58(11):1711\u20137. https:\/\/doi.org\/10.2967\/jnumed.116.185017.","journal-title":"J Nucl Medicine"},{"issue":"2","key":"5846_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3233\/JAD-171093","volume":"63","author":"ER Fantoni","year":"2018","unstructured":"Fantoni ER, Chalkidou A, O\u2019Brien JT, Farrar G, Hammers A. A Systematic review and aggregated analysis on the impact of amyloid PET Brain imaging on the diagnosis diagnostic confidence and management of patients being evaluated for Alzheimer\u2019s disease. J Alzheimers Dis. 2018;63(2):4. https:\/\/doi.org\/10.3233\/JAD-171093.","journal-title":"J Alzheimers Dis"},{"issue":"19","key":"5846_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1001\/jama.2015.4668","volume":"313","author":"WJ Jansen","year":"2015","unstructured":"Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FRJ, Visser PJ, Aalten P, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel H, van Berckel BNM, Bibeau K, Blennow K, Brooks DJ, van Buchem MA, Camus V, Cavedo E, Chen K, Chetelat G, Cohen AD, Drzezga A, Engelborghs S, Fagan AM, Fladby T, Fleisher AS, van der Flier WM, Ford L, F\u00f6rster S, Fortea J, Foskett N, Frederiksen KS, Freund-Levi Y, Frisoni GB, Froelich L, Gabryelewicz T, Gill KD, Gkatzima O, G\u00f3mez-Tortosa E, Gordon MF, Grimmer T, Hampel H, Hausner L, Hellwig S, Herukka S-K, Hildebrandt H, Ishihara L, Ivanoiu A, Jagust WJ, Johannsen P, Kandimalla R, Kapaki E, Klimkowicz-Mrowiec A, Klunk WE, K\u00f6hler S, Koglin N, Kornhuber J, Kramberger MG, Van Laere K, Landau SM, Lee DY, de Leon M, Lisetti V, Lle\u00f3 A, Madsen K, Maier W, Marcusson J, Mattsson N, de Mendon\u00e7a A, Meulenbroek O, Meyer PT, Mintun MA, Mok V, Molinuevo JL, M\u00f8llerg\u00e5rd HM, Morris JC, Mroczko B, Van der Mussele S, Na DL, Newberg A, Nordberg A, Nordlund A, Novak GP, Paraskevas GP, Parnetti L, Perera G, Peters O, Popp J, Prabhakar S, Rabinovici GD, Ramakers IHGB, Rami L, Resende de Oliveira C, Rinne JO, Rodrigue KM, Rodr\u00edguez-Rodr\u00edguez E, Roe CM, Rot U, Rowe CC, R\u00fcther E, Sabri O, Sanchez-Juan P, Santana I, Sarazin M, Schr\u00f6der J, Sch\u00fctte C, Seo SW, Soetewey F, Soininen H, Spiru L, Struyfs H, Teunissen CE, Tsolaki M, Vandenberghe R, Verbeek MM, Villemagne VL, Vos SJB, van Waalwijk LJC, van Doorn G, Waldemar A, Wallin \u00c5K, Wallin J, Wiltfang DA, Wolk M. Zboch, Zetterberg H. Prevalence of cerebral amyloid pathology in persons without dementia. JAMA. 2015;313(19):5. https:\/\/doi.org\/10.1001\/jama.2015.4668.","journal-title":"JAMA"},{"issue":"10","key":"5846_CR5","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/S1474-4422(14)70194-2","volume":"13","author":"CR Jack","year":"2014","unstructured":"Jack CR, Wiste HJ, Weigand SD, Rocca WA, Knopman DS, Mielke MM, Lowe VJ, Senjem ML, Gunter JL, Preboske GM, Pankratz VS, Vemuri P, Petersen RC. Age-specific population frequencies of cerebral \u03b2-amyloidosis and neurodegeneration among people with normal cognitive function aged 50\u201389 years: a cross-sectional study. Lancet Neurol. 2014;13(10):997\u20131005. https:\/\/doi.org\/10.1016\/S1474-4422(14)70194-2.","journal-title":"Lancet Neurol"},{"issue":"6","key":"5846_CR6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1212\/WNL.0b013e318245d295","volume":"78","author":"KM Rodrigue","year":"2012","unstructured":"Rodrigue KM, Kennedy KM, Devous MD, Rieck JR, Hebrank AC, Diaz-Arrastia R, Mathews D, Park DC. \u03b2-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology. 2012;78(6):2. https:\/\/doi.org\/10.1212\/WNL.0b013e318245d295.","journal-title":"Neurology"},{"issue":"24","key":"5846_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1212\/WNL.0000000000004733","volume":"89","author":"J Gonneaud","year":"2017","unstructured":"Gonneaud J, Arenaza-Urquijo EM, M\u00e9zenge F, Landeau B, Gaubert M, Bejanin A, de Flores R, Wirth M, Tomadesso C, Poisnel G, Abbas A, Desgranges B, Ch\u00e9telat G. Increased florbetapir binding in the temporal neocortex from age 20 to 60 years. Neurology. 2017;89(24):12. https:\/\/doi.org\/10.1212\/WNL.0000000000004733.","journal-title":"Neurology"},{"issue":"4","key":"5846_CR8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2967\/jnumed.118.211532","volume":"60","author":"LE Collij","year":"2019","unstructured":"Collij LE, Konijnenberg E, Reimand J, Kate MT, Braber AD, Alves IL, Zwan M, Yaqub M, van Assema DM, Wink AM, Lammertsma AA, Scheltens P, Visser PJ, Barkhof F, van Berckel BN. Assessing amyloid pathology in cognitively normal subjects using 18 F-Flutemetamol PET: comparing visual reads and quantitative methods. J Nucl Med. 2019;60(4):541\u20137. https:\/\/doi.org\/10.2967\/jnumed.118.211532.","journal-title":"J Nucl Med"},{"key":"5846_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3174\/ajnr.A4281","volume":"36","author":"AP Nayate","year":"2015","unstructured":"Nayate AP, Dubroff JG, Schmitt JE, Nasrallah I, Kishore R, Mankoff D, Pryma DA. Use of standardized uptake value ratios decreases interreader variability of [18F] florbetapir PET brain scan interpretation. Am J Neuroradiol. 2015;36:7. https:\/\/doi.org\/10.3174\/ajnr.A4281.","journal-title":"Am J Neuroradiol"},{"key":"5846_CR10","doi-asserted-by":"publisher","unstructured":"A Chincarini, E Peira, S Morbelli, M Pardini, M Bauckneht, J Arbizu, M Castelo-Branco, K B\u00fcsing, A de Mendon\u00e7a, M Didic, M Dottorini, S Engelborghs, C Ferrarese, G Frisoni, V Garibotto, E Guedj, L Hausner, J Hugon, J Verhaeghe, P Mecocci, M Musarra, M Queneau, M Riverol, I Santana, U Guerra and F Nobili. Semi-quantification and grading of amyloid PET: a project of the european Alzheimer\u2019s Disease Consortium (EADC). NeuroImage Clin. 2019; 23:101846. https:\/\/doi.org\/10.1016\/j.nicl.2019.101846.","DOI":"10.1016\/j.nicl.2019.101846"},{"issue":"7618","key":"5846_CR11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussi\u00e8re T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O\u2019Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature. 2016;537(7618):50\u20136. https:\/\/doi.org\/10.1038\/nature19323.","journal-title":"Nature"},{"issue":"15","key":"5846_CR12","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","volume":"380","author":"MF Egan","year":"2019","unstructured":"Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL, Tariot PN, Vellas B, van Dyck CH, Boada M, Zhang Y, Li W, Furtek C, Mahoney E, Harper Mozley L, Mo Y, Sur C, Michelson D. Randomized Trial of Verubecestat for prodromal Alzheimer\u2019s DISEASe. N Engl J Med. 2019;380(15):1408\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1812840.","journal-title":"N Engl J Med"},{"issue":"4","key":"5846_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370(4):1. https:\/\/doi.org\/10.1056\/NEJMoa1304839.","journal-title":"N Engl J Med"},{"issue":"4","key":"5846_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJMoa1705971","volume":"378","author":"LS Honig","year":"2018","unstructured":"Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, Hager K, Andreasen N, Scarpini E, Liu-Seifert H, Case M, Dean RA, Hake A, Sundell K, Poole Hoffmann V, Carlson C, Khanna R, Mintun M, DeMattos R, Selzler KJ, Siemers E. Trial of solanezumab for mild dementia due to Alzheimer\u2019s disease. N Engl J Med. 2018;378(4):1. https:\/\/doi.org\/10.1056\/NEJMoa1705971.","journal-title":"N Engl J Med"},{"issue":"1","key":"5846_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13195-016-0189-7","volume":"8","author":"R Vandenberghe","year":"2016","unstructured":"Vandenberghe R, Rinne JO, Boada M, Katayama S, Scheltens P, Vellas B, Tuchman M, Gass A, Fiebach JB, Hill D, Lobello K, Li D, McRae T, Lucas P, Evans I, Booth K, Luscan G, Wyman BT, Hua L, Yang L, Brashear HR, Black RS. Bapineuzumab for mild to moderate Alzheimer\u2019s disease in two global, randomized, phase 3 trials. Alzheimers Res Ther. 2016;8(1):12. https:\/\/doi.org\/10.1186\/s13195-016-0189-7.","journal-title":"Alzheimers Res Ther"},{"issue":"20","key":"5846_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1212\/WNL.0000000000004643","volume":"89","author":"MJ Grothe","year":"2017","unstructured":"Grothe MJ, Barthel H, Sepulcre J, Dyrba M, Sabri O, Teipel SJ. In vivo staging of regional amyloid deposition. Neurology. 2017;89(20):11. https:\/\/doi.org\/10.1212\/WNL.0000000000004643.","journal-title":"Neurology"},{"key":"5846_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1001\/jamaneurol.2019.2214","volume":"76","author":"N Mattsson","year":"2019","unstructured":"Mattsson N, Palmqvist S, Stomrud E, Vogel J, Hansson O. Staging \u03b2 -Amyloid Pathology with amyloid positron emission tomography. JAMA Neurol. 2019;76:11. https:\/\/doi.org\/10.1001\/jamaneurol.2019.2214.","journal-title":"JAMA Neurol"},{"issue":"1","key":"5846_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13195-019-0466-3","volume":"11","author":"FA Sakr","year":"2019","unstructured":"Sakr FA, Grothe MJ, Cavedo E, Jelistratova I, Habert M-O, Dyrba M, Gonzalez-Escamilla G, Bertin H, Locatelli M, Lehericy S, Teipel S, Dubois B, Hampel H. Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study. Alzheimers Res Ther. 2019;11(1):12. https:\/\/doi.org\/10.1186\/s13195-019-0466-3.","journal-title":"Alzheimers Res Ther"},{"issue":"6","key":"5846_CR19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1053\/j.sult.2010.10.001","volume":"31","author":"PE Kinahan","year":"2010","unstructured":"Kinahan PE, Fletcher JW. \u201cPositron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to Therapy\u201d Seminars in Ultrasound. CT and MRI. 2010;31(6):12. https:\/\/doi.org\/10.1053\/j.sult.2010.10.001.","journal-title":"CT and MRI"},{"issue":"4","key":"5846_CR20","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.3233\/JAD-160232","volume":"54","author":"A Chincarini","year":"2016","unstructured":"Chincarini A, Sensi F, Rei L, Bossert I, Morbelli S, Guerra UP, Frisoni G, Padovani A, Nobili F. Standardized uptake value ratio-independent evaluation of brain amyloidosis. J Alzheimers Dis. 2016;54(4):1437\u201357. https:\/\/doi.org\/10.3233\/JAD-160232.","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"5846_CR21","doi-asserted-by":"publisher","first-page":"536","DOI":"10.2967\/jnumed.118.210518","volume":"60","author":"A Whittington","year":"2019","unstructured":"Whittington A, Gunn RN. Amyloid Load: a more sensitive biomarker for amyloid imaging. J Nucl Med. 2019;60(4):536\u201340. https:\/\/doi.org\/10.2967\/jnumed.118.210518.","journal-title":"J Nucl Med"},{"issue":"9","key":"5846_CR22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s00259-020-04689-y","volume":"47","author":"A Chincarini","year":"2020","unstructured":"Chincarini A, Peira E, Corosu M, Morbelli S, Bauckneht M, Capitanio S, Pardini M, Arnaldi D, Vellani C, D\u2019Ambrosio D, Garibotto V, Assal F, Paghera B, Savelli G, Stefanelli A, Guerra UP, Nobili F. A kinetics-based approach to amyloid PET semi-quantification. Eur J Nucl Med Mol Imaging. 2020;47(9):8. https:\/\/doi.org\/10.1007\/s00259-020-04689-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"5846_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00259-017-3750-0","volume":"44","author":"D Cecchin","year":"2017","unstructured":"Cecchin D, Barthel H, Poggiali D, Cagnin A, Tiepolt S, Zucchetta P, Turco P, Gallo P, Frigo AC, Sabri O, Bui F. A new integrated dual time-point amyloid PET\/MRI data analysis method. Eur J Nucl Med Mol Imaging. 2017;44(12):11. https:\/\/doi.org\/10.1007\/s00259-017-3750-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"5846_CR24","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.jalz.2014.09.004","volume":"11","author":"ME Schmidt","year":"2015","unstructured":"Schmidt ME, Chiao P, Klein G, Matthews D, Thurfjell L, Cole PE, Margolin R, Landau S, Foster NL, Mason NS, De Santi S, Suhy J, Koeppe RA, Jagust W. The influence of biological and technical factors on quantitative analysis of amyloid PET: points to consider and recommendations for controlling variability in longitudinal data. Alzheimers Dement. 2015;11(9):1050\u201368. https:\/\/doi.org\/10.1016\/j.jalz.2014.09.004.","journal-title":"Alzheimers Dement"},{"issue":"7","key":"5846_CR25","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.2967\/jnumed.117.200964","volume":"59","author":"S Bullich","year":"2018","unstructured":"Bullich S, Barthel H, Koglin N, Becker GA, De Santi S, Jovalekic A, Stephens AW, Sabri O. Validation of noninvasive tracer kinetic analysis of 18 F-Florbetaben PET using a dual\u2013time-window acquisition protocol. J Nucl Med. 2018;59(7):1104\u201310. https:\/\/doi.org\/10.2967\/jnumed.117.200964.","journal-title":"J Nucl Med"},{"issue":"10","key":"5846_CR26","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1007\/s00259-021-05485-y","volume":"48","author":"V Garibotto","year":"2021","unstructured":"Garibotto V, Albert NL, Barthel H, van Berckel B, Boellaard R, Brendel M, Cecchin D, Ekmekcioglu O, van de Giessen E, Guedj E, Lammerstma AA, Semah F, Traub-Weidinger T, Van Weehaeghe D, Morbelli S. The approval of a disease-modifying treatment for Alzheimer\u2019s disease: impact and consequences for the nuclear medicine community. Eur J Nucl Med Mol Imaging. 2021;48(10):3033\u20136. https:\/\/doi.org\/10.1007\/s00259-021-05485-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5846_CR27","unstructured":"European Medicines Agency. Neuraceq: florbetaben (18F). Product information. 1999. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/neuraceq. Accessed 10 Jan 2022."},{"issue":"8","key":"5846_CR28","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.2967\/jnumed.116.174615","volume":"57","author":"S Minoshima","year":"2016","unstructured":"Minoshima S, Drzezga AE, Barthel H, Bohnen N, Djekidel M, Lewis DH, Mathis CA, McConathy J, Nordberg A, Sabri O, Seibyl JP, Stokes MK, Van Laere K. SNMMI Procedure standard\/EANM practice guideline for amyloid PET imaging of the brain 1.0. J Nucl Med. 2016;57(8):1316\u201322. https:\/\/doi.org\/10.2967\/jnumed.116.174615.","journal-title":"J Nucl Med"},{"issue":"2","key":"5846_CR29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.neuroimage.2012.01.021","volume":"62","author":"B Fischl","year":"2012","unstructured":"Fischl B. FreeSurfer. NeuroImage. 2012;62(2):8. https:\/\/doi.org\/10.1016\/j.neuroimage.2012.01.021.","journal-title":"NeuroImage"},{"issue":"1","key":"5846_CR30","doi-asserted-by":"publisher","first-page":"493","DOI":"10.21037\/qims-21-188","volume":"12","author":"EG M\u00fcller","year":"2022","unstructured":"M\u00fcller EG, Stokke C, Stokmo HL, Edwin TH, Knapskog AB, Revheim ME. Evaluation of semi-quantitative measures of 18 F-flutemetamol PET for the clinical diagnosis of Alzheimer\u2019s disease. Quant Imaging Med Surg. 2022;12(1):493\u2013509.","journal-title":"Quant Imaging Med Surg"},{"issue":"8","key":"5846_CR31","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.2967\/jnumed.114.152405","volume":"56","author":"YJ Chen","year":"2015","unstructured":"Chen YJ, Rosario BL, Mowrey W, Laymon CM, Lu X, Lopez OL, Klunk WE, Lopresti BJ, Mathis CA, Price JC. Relative 11C-pib delivery as a proxy of relative CBF: quantitative evaluation using single-session 15O-water and 11C-pib PET. J Nucl Med. 2015;56(8):1199\u2013205. https:\/\/doi.org\/10.2967\/jnumed.114.152405.","journal-title":"J Nucl Med"},{"issue":"9","key":"5846_CR32","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1007\/s00259-016-3353-1","volume":"43","author":"S Tiepolt","year":"2016","unstructured":"Tiepolt S, Hesse S, Patt M, Luthardt J, Schroeter ML, Hoffmann KT, Weise D, Gertz HJ, Sabri O, Barthel H. Early [(18)F]florbetaben and [(11)C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2016;43(9):1700\u20139. https:\/\/doi.org\/10.1007\/s00259-016-3353-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5846_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.nicl.2016.10.005","volume":"14","author":"S Daerra","year":"2017","unstructured":"Daerra S, Brendel M, Zach C, Mille E, Schilling D, Zacherl MJ, B\u00fcrger K, Danek A, Pogarell O, Schildan A, Patt M, Barthel H, Sabri O, Bartenstein P, Rominger A. Evaluation of early-phase [18F]-florbetaben PET acquisition in clinical routine cases. Neuroimage: Clin. 2017;14:77\u201386. https:\/\/doi.org\/10.1016\/j.nicl.2016.10.005.","journal-title":"Neuroimage: Clin"},{"key":"5846_CR34","doi-asserted-by":"publisher","first-page":"661284","DOI":"10.3389\/fnagi.2021.661284","volume":"13","author":"J Schmitt","year":"2021","unstructured":"Schmitt J, Palleis C, Sauerbeck J, Unterrainer M, Harris S, Prix C, Weidinger E, Katzdobler S, Wagemann O, Danek A, Beyer L, Rauchmann BS, Rominger A, Simons M, Bartenstein P, Perneczky R, Haass C, Levin J, H\u00f6glinger GU, Brendel M, the German Imaging Initiative for Tauopathies (GII4T). Dual-phase \u03b2-amyloid PET Captures neuronal injury and amyloidosis in corticobasal syndrome. Front Aging Neurosci. 2021;13:661284. https:\/\/doi.org\/10.3389\/fnagi.2021.661284.","journal-title":"Front Aging Neurosci"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-05846-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-022-05846-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-05846-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T17:04:30Z","timestamp":1664557470000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-022-05846-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["5846"],"URL":"https:\/\/doi.org\/10.1007\/s00259-022-05846-1","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,2]]},"assertion":[{"value":"11 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"D.C. received a research grant from Life molecular imaging and from GE for amyloid researches, O.S. received research grants from Life Molecular Imaging, H.B. received speaker honoraria from AAA\/Novartis, and S.M. received speaker honoraria from GE Healthcare and Life Molecular Imaging. The other authors declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}